For information about genetic testing for hereditary cancer, visit [ Ссылка ]

In this webinar, we will review the mechanism of action of PARP inhibitors including the principle of synthetic lethality and the cellular basis for PARP inhibitor activity. We will then review some of the seminal clinical trials leading to FDA approval of PARP inhibitors in the context of ovarian cancer, metastatic breast cancer, and pancreas cancer. Finally, we will discuss select clinical trials representative of directions of future PARP inhibitor development.

Presented by:
Payal D. Shah, MD | Presenter
Brissa Martin, MS, CGC | Moderator

Dr. Payal Shah is an Assistant Professor of Medicine in at the Basser Center for BRCA and the Abramson Cancer Center at the University of Pennsylvania. She is a medical oncologist and clinical investigator specializing in breast cancer and cancer genetics and conducts clinical trials examining targeted therapy and immunotherapy. She is the recipient of several awards including a Susan G. Komen Career Catalyst Award and an ASCO Conquer Cancer Foundation Young Investigator Award.

свернуть